Targanta Therapeutics Corp.·4

Feb 27, 4:14 PM ET

Courtney Jeffrey 4

4 · Targanta Therapeutics Corp. · Filed Feb 27, 2009

Insider Transaction Report

Form 4
Period: 2009-02-25
Transactions
  • Disposition from Tender

    Common Stock

    2009-02-25106,1490 total(indirect: See footnote.)
  • Disposition from Tender

    Common Stock

    2009-02-251,523,2100 total(indirect: See footnote.)
Footnotes (3)
  • [F1]The shares were tendered in a tender offer by Boxford Subsidiary Corporation for consideration of (1) $2.00 per common share in cash, plus (2) the contractual right to receive up to an additional $4.55 per common share in contingent cash payments if specified regulatory and commercial milestones are achieved within agreed upon time periods.
  • [F2]Shares held by VenGrowth III Investment Fund. Mr. Courtney is a General Partner of VenGrowth III Investment Fund and, as such, may be deemed to hold voting and dispositive power with respect to all shares of common stock held by VenGrowth III Investment Fund. Mr. Courtney disclaims beneficial ownership of the shares held by VenGrowth III Investment Fund except to the extent of his pecuniary interest, if any, in such shares.
  • [F3]Shares held by VenGrowth Advanced Life Sciences Fund. Mr. Courtney is a General Partner of VenGrowth Advanced Life Sciences Fund and, as such, may be deemed to hold voting and dispositive power with respect to all shares of common stock held by VenGrowth Advanced Life Sciences Fund. Mr. Courtney disclaims beneficial ownership of the shares held by VenGrowth Advanced Life Sciences Fund except to the extent of his pecuniary interest, if any, in such shares.

Documents

1 file
  • 4
    c81842_4x0.xmlPrimary

    MAIN DOCUMENT DESCRIPTION